Citius Pharmaceuticals Poised for Growth with Key Milestones and Promising Product Pipeline

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Citius Pharmaceuticals (CTXR – Research Report), with a price target of $4.00.

Vernon Bernardino has given his Buy rating due to a combination of factors related to Citius Pharmaceuticals’ recent achievements and future potential. A significant milestone was reached with the assignment of a permanent J-code for Lymphir by the Centers for Medicare and Medicaid Services, which is expected to facilitate its commercialization and reimbursement process. This development positions Citius to potentially launch Lymphir in the first half of 2025, enhancing its market prospects.
Additionally, the positive results from the pivotal Phase 3 clinical trial of Mino-Lok, an antibiotic lock solution, indicate a promising future for this product as well. With both Lymphir and Mino-Lok potentially entering the market by the first half of 2026, Citius Pharmaceuticals is poised for significant growth. The FDA’s constructive guidance on the New Drug Application pathway for Mino-Lok further supports this outlook. As a result, Bernardino reiterates a Buy rating, adjusting the price target post-reverse stock split to $4.

According to TipRanks, Bernardino is an analyst with an average return of -5.1% and a 21.26% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Candel Therapeutics, Cassava Sciences, and Aethlon Medical.